Alamar Biosciences, Inc. 8-K

What Happened

• On May 8, 2026, Alamar Biosciences, Inc. announced its financial results for the quarter ended March 31, 2026 via a press release. The company filed an 8-K (Item 2.02) to furnish those results and attached the press release as Exhibit 99.1, which is incorporated by reference into the filing.

Key Details

• Filing date: May 8, 2026; reporting period: quarter ended March 31, 2026.
• The press release announcing the quarterly results is attached to the 8-K as Exhibit 99.1.
• The 8-K was signed by Justin McAnear, Chief Financial Officer (Principal Financial and Accounting Officer).
• The 8-K furnishes results of operations and financial condition (Item 2.02); the detailed financial figures and metrics are contained in the attached press release.

Why It Matters

• Quarterly results can affect investor views on earnings, revenue trends, and the company’s financial health; the 8-K signals that Alamar has released new financial information.
• Retail investors should review the attached press release (Exhibit 99.1) or the company’s filings on EDGAR to see the specific revenue, earnings, cash flow or guidance details disclosed.
• This 8-K itself does not present numeric results in-line; the press release is the primary source for the reported quarterly figures.